What’s Johnson & Johnson’s Pharmaceuticals Segment?

Johnson & Johnson’s Valuation Improves after Its 2Q16 Results PART 4 OF 8 By Mike Benson  | Aug 30, 2016 12:19 pm EDT Pharmaceuticals segment Johnson & Johnson’s (JNJ) Pharmaceuticals segment includes the following—immunology, infectious disease, neuroscience, oncology, and cardiovascular and metabolics. Neuroscience franchise The neuroscience franchise consists of drugs like Concerta, Invega Sustenna, and Xeplion. The neuroscience franchise revenues rose by 2.4% to $1.6 billion in 2Q16 including an operational increase of 2.8%. It was partially offset by a 0.4% negative impact of foreign exchange. Invega Trinza and Xeplion were the growth drivers for long-acting injectable products. However, US sales were impacted by lower sales of Invega due to competitive products. Immunology franchise The major blockbuster drugs under this franchise are Remicade, Stelara, and Simponi/Simponi Aria. The immunology franchise’s…


Link to Full Article: What’s Johnson & Johnson’s Pharmaceuticals Segment?